Women’s Viagra: Stentor – Now Available in the US
‘Female Viagra’ Now Available in teh U.S. After Decades of Waiting
Table of Contents
Published December 14, 2025
A New Option for Addressing Female Sexual Dysfunction
After approximately 30 years since the introduction of medications to treat erectile dysfunction in men, the U.S.Food and Drug Administration (FDA) has approved a medication specifically designed to address hypoactive sexual desire disorder (HSDD) in premenopausal women. This marks a important milestone in womenS health, offering a pharmacological option for a condition that affects millions.
The newly approved drug, bremelanotide, marketed under the brand name Vyleesi, is a melanocortin receptor agonist administered via a self-injection. Unlike Viagra, which directly affects blood flow, Vyleesi works on the central nervous system to increase sexual desire.The FDA approved Vyleesi in June 2019, but its availability has been limited until recently.
Understanding HSDD and the Need for Targeted Treatment
HSDD is characterized by a persistent or recurrent deficiency in sexual fantasies and desire, causing distress or interpersonal difficulty. It’s important to note that a low sex drive is common and doesn’t automatically indicate HSDD; the condition requires a formal diagnosis by a healthcare professional. Factors contributing to HSDD can be complex, including psychological, hormonal, and relationship issues.
Prior to Vyleesi, treatment options for HSDD were limited to counseling, psychotherapy, and, in some cases, hormone therapy. The approval of a dedicated medication acknowledges the biological component of sexual desire in women and provides a new avenue for treatment. Another medication, flibanserin (Addyi), was approved by the FDA in 2015, but carries more restrictions and potential side effects.
Availability and Considerations
Currently, Vyleesi is only available in the United states. The medication is not intended for use as an “on-demand” treatment like Viagra; it’s designed to be used as needed, but not more than once in 24 hours, and should be administered at least 45 minutes before anticipated sexual activity.
Potential side effects of Vyleesi include nausea, flushing, headache, and injection site reactions. it is also contraindicated for individuals with certain medical conditions, such as uncontrolled high blood pressure.Patients interested in Vyleesi should consult with their healthcare provider to determine if it’s a suitable option and to discuss potential risks and benefits.